Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy

Fineline Cube Jul 2, 2026
Company Deals Digital

Insilico Medicine and Takeda Launch $600M Strategic AI Drug Discovery Collaboration – Pharma.AI Platform to Drive Candidate Identification for High-Potential Therapeutic Targets

Fineline Cube Jul 2, 2026
Company Deals

Nona Biosciences and Lonza Forge Strategic Alliance to Develop Best-in-Class Blood-Brain Barrier Penetration Technology for CNS Therapeutics

Fineline Cube Jul 2, 2026
Company Deals

Ipsen to Acquire Memo Therapeutics for €200M Plus Milestones, Gaining Phase II BK Virus Antibody Potravitug for Transplant Nephropathy

Fineline Cube Jul 2, 2026
Company Deals

Ribo Life Science Achieves First Milestone in siRNA Collaboration with Madrigal for MASH Therapeutics

Fineline Cube Jul 2, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

Hangzhou Adamerck’s Aom0498 Receives NMPA Approval as China’s First Homegrown Neuromuscular Blockade Reversal Agent – Completing Decade-Long National Innovation Program

Fineline Cube Jul 2, 2026
Company Drug

Jingxin Pharmaceutical Secures NMPA Approval for China’s First Generic Cariprazine in Schizophrenia – Capturing Market Opportunity as Reference Product Remains Unlaunched

Fineline Cube Jul 2, 2026
Company Drug

CDE Approves RinuaGene’s mRNA-Based RG002 for Clinical Study in Cervical Dysplasia

Fineline Cube Dec 6, 2024

China’s Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has indicated...

Company

Burning Rock Ltd Reports Q3 2024 Financials with Revenue Growth and R&D Reduction

Fineline Cube Dec 5, 2024

China-based medtech firm Burning Rock Ltd (NASDAQ: BNR) has released its financial results for the...

Company Deals

Novavax to Sell Czech Manufacturing Facility to Novo Nordisk for $200 Million

Fineline Cube Dec 5, 2024

US-based Novavax, Inc. (NASDAQ: NVAX) has reached an agreement to sell its manufacturing facility located...

Hospital Policy / Regulatory

China’s Health Commission Issues Guidelines to Strengthen Ties Between Healthcare and Elderly Care

Fineline Cube Dec 5, 2024

The National Health Commission, in conjunction with three other bureaus, has issued the “Notice on...

Company Drug

Eli Lilly’s Zepbound Outperforms Wegovy in SURMOUNT-5 Weight Loss Study

Fineline Cube Dec 5, 2024

US pharmaceutical major Eli Lilly & Co., (NYSE: LLY) has revealed a positive readout from...

Company Drug

Phanes Therapeutics’ PT217 Earns FDA Fast Track Designation for Neuroendocrine Prostate Cancer

Fineline Cube Dec 5, 2024

Sino-US biotech company Phanes Therapeutics Inc. has announced that it has received another Fast Track...

Company Drug

CGeneTech’s Cetagliptin Receives NMPA Approval for Type 2 Diabetes Treatment in China

Fineline Cube Dec 5, 2024

The National Medical Products Administration (NMPA) in China has indicated on its website that CGeneTech...

Company Drug

Eisai and Biogen’s Leqembi Approved in Mexico for Early Alzheimer’s Disease Treatment

Fineline Cube Dec 5, 2024

Eisai Co., Ltd (TYO: 4523) and Biogen Inc. (NASDAQ: BIIB) have announced that their co-developed...

Company

AstraZeneca Appoints Iskra Reic as EVP, International, Amid Leon Wang’s Investigation in China

Fineline Cube Dec 5, 2024

AstraZeneca (AZ, NASDAQ: AZN), a leading UK pharmaceutical company, has announced the appointment of Iskra...

Company Drug

Shanghai Escugen Receives NMPA Approval for Second Phase III Trial of ESG401 in TNBC

Fineline Cube Dec 5, 2024

Shanghai Escugen, a China-based biopharmaceutical company, has announced receiving the green light from the National...

Company Drug

Johnson & Johnson Submits sBLAs to FDA for Tremfya Indications in Pediatric Psoriasis and Arthritis

Fineline Cube Dec 5, 2024

Global healthcare giant Johnson & Johnson (J&J; NYSE: JNJ) has announced the submission of two...

Company Deals

GSK plc Expands Pipeline with Rgenta Therapeutics Partnership for RNA-Targeted Splice Modulators

Fineline Cube Dec 5, 2024

GSK plc (NYSE: GSK), a leading global pharmaceutical company, continues to bolster its pipeline through...

Company Drug

Merus N.V. Receives FDA Approval for Bizengri for NRG1+ Pancreatic and Lung Cancers

Fineline Cube Dec 5, 2024

Holland-based Merus N.V. (NASDAQ: MRUS) has announced that it has received FDA approval for its...

Company Drug

Ipsen’s Bylvay Receives NMPA Clearance for Treating Itching in PFIC Patients in China

Fineline Cube Dec 5, 2024

France-based Ipsen (EPA: IPN) has announced that it has received marketing clearance from the National...

Company Drug

Tasly Pharma Receives NMPA Approval for Generic Lioresal (Baclofen) Oral Solution

Fineline Cube Dec 5, 2024

China-based Tasly Pharma Co., Ltd (SHA: 600535) has announced that it has received marketing approval...

Company Drug

Humanwell Healthcare’s Recombinant Plasmid Hepatocyte Growth Factor Injection Accepted for NMPA Review

Fineline Cube Dec 5, 2024

China-based Humanwell Healthcare (Group) Co., Ltd (SHA: 600079) has announced that the National Medical Products...

Company Drug

Haisco Pharmaceutical’s HSK46575 Receives NMPA Approval for Prostate Cancer Clinical Trial

Fineline Cube Dec 5, 2024

China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced the receipt of clinical trial...

Company Drug

Sichuan Kelun-Biotech’s SKB500 Receives NMPA Clinical Clearance for Solid Tumor Treatment

Fineline Cube Dec 5, 2024

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd, (HKG: 6990), a leading biopharmaceutical company based in China, has...

Company Drug

Cinclus Pharma’s Linaprazan for GERD Receives NMPA Marketing Approval

Fineline Cube Dec 5, 2024

Sweden-based Cinclus Pharma has announced that it has received marketing approval from the National Medical...

Company

CSPC Pharmaceutical’s CRB-701 Earns FDA Fast Track Designation for Cervical Cancer Treatment

Fineline Cube Dec 5, 2024

China-based CSPC Pharmaceutical Group Co., Ltd (HKG: 1093) has announced that it has received Fast...

Posts pagination

1 … 276 277 278 … 690

Recent updates

  • Hangzhou Adamerck’s Aom0498 Receives NMPA Approval as China’s First Homegrown Neuromuscular Blockade Reversal Agent – Completing Decade-Long National Innovation Program
  • Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy
  • Jingxin Pharmaceutical Secures NMPA Approval for China’s First Generic Cariprazine in Schizophrenia – Capturing Market Opportunity as Reference Product Remains Unlaunched
  • TransThera Completes Patient Enrollment in Global Phase III Trial of Tinengotinib for Advanced Cholangiocarcinoma – Multi-Kinase Inhibitor Backed by Multiple Regulatory Designations
  • TransThera Advances Phase II Trial of Selective BTK Inhibitor TT-01488 with Anti-CD20 Antibodies for Mantle Cell Lymphoma – Novel Non-Covalent Approach Shows Enhanced Safety Profile
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hangzhou Adamerck’s Aom0498 Receives NMPA Approval as China’s First Homegrown Neuromuscular Blockade Reversal Agent – Completing Decade-Long National Innovation Program

Company Deals

Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy

Company Drug

Jingxin Pharmaceutical Secures NMPA Approval for China’s First Generic Cariprazine in Schizophrenia – Capturing Market Opportunity as Reference Product Remains Unlaunched

Company Drug

TransThera Completes Patient Enrollment in Global Phase III Trial of Tinengotinib for Advanced Cholangiocarcinoma – Multi-Kinase Inhibitor Backed by Multiple Regulatory Designations

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.